Blood brain barrier state of a disease the chronic obstructive pulmonary disease-Central side effect measures of the inhalational anti-cholinergic drugs

慢性阻塞性肺疾病的血脑屏障状态-吸入性抗胆碱能药物的中枢副作用测定

• 批准号: 22790177
• 负责人: TOMINAGA Koji
• 金额: $ 2.58万
• 依托单位: Fukuoka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22790177/
• 关键词: 医療薬剤学; COPD; BBB; 中枢性副作用; 炎症; 血液脳関門; ペリサイト

We examined a change of the blood-brain barrier(BBB) function and the central nerve transition of the anticholinergic drugs in the chronic obstructive pulmonary disease(COPD). As result, in COPD model mouse, tight junction function of the BBB was decreased, and there is possibility that the intracerebral transmissiveness of the anticholinergic drug were aggravated. Therefore, in COPD, the brain internal transmigration of drugs are accelerated by BBB disfunction, and it was thought that expression of the central side effects such as cognitive function disorders are easy.

我们研究了慢性阻塞性肺疾病（COPD）患者血脑屏障（BBB）功能的改变和抗胆碱能药物对中枢神经的影响。结果，慢性阻塞性肺疾病模型小鼠血脑屏障紧密连接功能下降，可能加重了抗胆碱能药物的脑内传递性。因此，在COPD中，药物的脑内转运因血脑屏障功能障碍而加速，并被认为容易表达认知功能障碍等中枢副作用。